Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gong Tang

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
Breast Cancer Research and Treatment|March 22, 2023
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41Priya Rastogi, Gong Tang, Saima Hassan, et al.
The Lancet. Oncology|October 8, 2013
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trialAndré Robidoux, Gong Tang, Priya Rastogi, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trialSandra M Swain, Gong Tang, Charles E Geyer, et al.
The Lancet. Oncology|August 15, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trialHarry D Bear, Gong Tang, Priya Rastogi, et al.
The New England Journal of Medicine|January 27, 2012
Bevacizumab added to neoadjuvant chemotherapy for breast cancerHarry D Bear, Gong Tang, Priya Rastogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2011
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancerChungyeul Kim, Gong Tang, Katherine L Pogue-Geile, et al.
The American Journal of Gastroenterology|June 6, 2018
Recurrent Acute Pancreatitis Significantly Reduces Quality of Life Even in the Absence of Overt Chronic PancreatitisGregory A Coté, Dhiraj Yadav, Judah A Abberbock, et al.
Annals of Surgical Oncology|November 20, 2016
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40Harry D Bear, Gong Tang, Priya Rastogi, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|November 20, 2022
Acute pancreatitis precedes chronic pancreatitis in the majority of patients: Results from the NAPS2 consortiumVikesh K Singh, David C Whitcomb, Peter A Banks, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Breast Cancer Research and Treatment|March 22, 2023
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41Priya Rastogi, Gong Tang, Saima Hassan, et al.
The Lancet. Oncology|October 8, 2013
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trialAndré Robidoux, Gong Tang, Priya Rastogi, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trialSandra M Swain, Gong Tang, Charles E Geyer, et al.
The Lancet. Oncology|August 15, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trialHarry D Bear, Gong Tang, Priya Rastogi, et al.
The New England Journal of Medicine|January 27, 2012
Bevacizumab added to neoadjuvant chemotherapy for breast cancerHarry D Bear, Gong Tang, Priya Rastogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2011
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancerChungyeul Kim, Gong Tang, Katherine L Pogue-Geile, et al.
The American Journal of Gastroenterology|June 6, 2018
Recurrent Acute Pancreatitis Significantly Reduces Quality of Life Even in the Absence of Overt Chronic PancreatitisGregory A Coté, Dhiraj Yadav, Judah A Abberbock, et al.
Annals of Surgical Oncology|November 20, 2016
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40Harry D Bear, Gong Tang, Priya Rastogi, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|November 20, 2022
Acute pancreatitis precedes chronic pancreatitis in the majority of patients: Results from the NAPS2 consortiumVikesh K Singh, David C Whitcomb, Peter A Banks, et al.
Pageof 12